In contrast, transcriptome analysis and siRNA library showed that diverse epigenetic mechanisms intricately affect the adaptive resistance in ALK-rearranged lung cancer, indicating that EGFR is involved in part of the adaptive response to lorlatinib. The gene discussed is EGFR; the disease is lung cancer.